Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes

2384 patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS) from four randomized trials who underwent in-hospital PCI and had CK-MB levels measured <=24h after PCI (excluding those with elevated CK or CK-MB levels <24h before PCI).

Peak CK-MB elevation after PCI (analyzed as peak CK-MB level/upper limit of normal [ULN])

Lower or normal peak CK-MB levels after PCI

In-hospital heart failure, arrhythmias, cardiogenic shock, and mortality through 6 monthshard clinical